You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The complaint, filed yesterday, alleges that Illumina's two-channel sequencing systems infringe Complete Genomics' US Patent No. 9,222,132.
PGDx, the defendant in the liquid biopsy IP case, has alleged that Guardant's CEO should have been named as an inventor on patents but was purposefully left off.
The lawsuit follows a similar one that Illumina filed earlier this year in Germany against Latvia MGI Tech, another subsidiary of BGI Group.
The plaintiffs are concerned by the growth of DNA databases for law enforcement and want the government to automatically delete profiles of people not convicted of felonies.
New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The New York Times Magazine examines gender discrimination at the Salk Institute.
The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.
The suit alleges that BGI's sequencing products and reagents infringe a European patent held by Illumina.
CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.